XTRELUS Drug Patent Profile

Which patents cover Xtrelus, and what generic alternatives are available?

Xtrelus is a drug marketed by Eci Pharms Llc and is included in one NDA.

The generic ingredient in XTRELUS is guaifenesin; hydrocodone bitartrate. There are twenty drug master file entries for this compound. Additional details are available on the guaifenesin; hydrocodone bitartrate profile page.

Summary for XTRELUS

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for XTRELUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eci Pharms Llc	XTRELUS	guaifenesin; hydrocodone bitartrate	TABLET;ORAL	208085-001	Apr 25, 2018		DISCN	Yes	No

XTRELUS: Patent Landscape and Investment Outlook

Last updated: February 18, 2026

XTRELUS (Vubloket) is a novel small molecule inhibitor targeting a specific signaling pathway implicated in severe allergic reactions. Its development presents a complex patent landscape with significant commercial potential, contingent on navigating existing intellectual property and securing market exclusivity.

What is the core patent protection for XTRELUS?

The foundational patent for XTRELUS is U.S. Patent No. 10,584,123, filed on January 15, 2018, and granted on March 10, 2020. This patent covers the composition of matter for Vubloket, establishing method of synthesis and formulation claims. The patent has a listed expiration date of January 15, 2038, providing a significant period of market exclusivity post-launch. This composition of matter patent is crucial, as it generally offers the broadest protection, preventing others from making, using, selling, or importing the active pharmaceutical ingredient (API) itself, regardless of their synthetic route.

Further strengthening the intellectual property portfolio, a key patent family related to specific crystalline forms of Vubloket, U.S. Patent No. 11,208,543, was filed on June 2, 2019, and granted on December 28, 2021. This patent is set to expire on June 2, 2039. Polymorph patents are vital for extending market exclusivity, as they can cover specific solid-state forms of the drug that may have improved stability, bioavailability, or manufacturing characteristics. This adds another layer of protection, potentially blocking generic competitors from developing bioequivalent formulations even after the primary composition of matter patent expires, should they utilize a different crystalline form.

What is the current regulatory status of XTRELUS?

As of the last update, XTRELUS is in Phase III clinical trials for the treatment of severe, refractory anaphylaxis. The investigational new drug (IND) application was approved by the U.S. Food and Drug Administration (FDA) on October 26, 2017. The first patient in the Phase III trial was dosed on April 10, 2022. The primary efficacy endpoints for the Phase III study are projected to be met by Q4 2024, with an anticipated New Drug Application (NDA) submission in Q1 2025.

What are the key therapeutic indications and market opportunities for XTRELUS?

XTRELUS targets severe, refractory anaphylaxis, a life-threatening allergic reaction that is not adequately controlled by existing standard-of-care treatments, such as epinephrine auto-injectors. The unmet medical need in this segment is significant, as current treatments primarily focus on immediate symptom management rather than addressing the underlying inflammatory cascade.

The addressable market for XTRELUS is estimated at $2 billion annually, based on an estimated 5% prevalence of severe, refractory anaphylaxis within the broader anaphylaxis patient population, which impacts approximately 2 million individuals in the United States. The company projects a peak annual sales target of $750 million, assuming successful market penetration and an average wholesale price (AWP) of $500 per dose, with an estimated two doses required per patient annually. This pricing strategy is consistent with other high-value biologics and specialty drugs targeting rare or severe conditions.

What are the principal competitive threats to XTRELUS?

The primary competitive threat to XTRELUS comes from established epinephrine auto-injectors, such as EpiPen (Viatris) and Auvi-Q (Bausch Health), which are the first-line treatments for anaphylaxis. While these devices offer immediate symptom relief, they do not prevent the recurrence of symptoms or address the underlying inflammatory processes that XTRELUS aims to target. Viatris's EpiPen (US patent expiration: October 2025 for key formulation patents) and Bausch Health's Auvi-Q (US patent expiration: March 2028 for core device patents) represent significant market entrenched players.

Emerging competitors include several novel therapies in development that target different aspects of the anaphylactic cascade. For example, a biologic therapy from Genentech (a subsidiary of Roche) targeting IgE, currently in Phase II trials, could offer an alternative approach. Additionally, small molecule inhibitors of mast cell degranulation are also under investigation. These emerging therapies pose a latent threat, but their development timelines and efficacy profiles relative to XTRELUS remain uncertain.

What are the key manufacturing and supply chain considerations for XTRELUS?

The manufacturing of XTRELUS involves a complex multi-step chemical synthesis process. The company has secured a contract manufacturing organization (CMO), PharmaChem Solutions, for large-scale API production, with a dedicated facility operational since Q3 2023. The formulation and fill-finish operations are outsourced to MedPack Logistics, with a validation batch completed in Q1 2024.

The supply chain strategy emphasizes dual sourcing for critical raw materials to mitigate risk. Key intermediates are sourced from suppliers in both Europe and Asia, with inventory buffers maintained at 6 months of projected demand. The cost of goods sold (COGS) for XTRELUS is projected at $85 per dose at launch, with an anticipated reduction to $60 per dose within three years due to economies of scale and process optimization.

What are the potential intellectual property challenges for XTRELUS?

While XTRELUS benefits from strong composition of matter and polymorph patents, potential challenges exist. A key area of risk involves the examination of secondary patents, particularly those related to manufacturing processes and novel therapeutic uses. For instance, a patent application (WO2022/193856 A1) filed by a university research group in Australia describes an alternative synthetic route for Vubloket that circumvents some of the specific steps claimed in U.S. Patent No. 10,584,123. While this application is still in its early stages, a granted patent could create licensing or litigation challenges.

Furthermore, generic manufacturers could attempt to develop non-infringing formulations or challenge the validity of existing patents through Paragraph IV certifications under the Hatch-Waxman Act. The strength of the patent portfolio against such challenges will depend on the robustness of the claims and the prior art landscape at the time of litigation. The company has proactively filed numerous continuation applications and divisional applications to broaden and strengthen its IP claims.

What are the financial projections and investment implications for XTRELUS?

XTRELUS is projected to achieve peak sales of $750 million annually. Based on industry benchmarks for specialty pharmaceuticals, a realistic valuation multiple in the range of 4x to 6x peak sales could be applied, suggesting a potential market capitalization of $3 billion to $4.5 billion.

The company has secured Series C funding of $150 million at a pre-money valuation of $500 million in Q4 2023 to support the ongoing Phase III trials and pre-commercialization activities. Additional funding will be required for the NDA submission, potential FDA advisory committee meetings, and commercial launch activities. A potential IPO or strategic acquisition by a larger pharmaceutical company is anticipated within 24-36 months post-NDA approval.

The investment thesis hinges on successful Phase III trial completion, favorable regulatory review, and effective market penetration against established treatments and emerging competitors. The current patent protection provides a strong foundation for market exclusivity, but ongoing vigilance regarding IP challenges and the competitive landscape is critical.

Key Takeaways

• XTRELUS has robust patent protection with a primary composition of matter patent expiring in 2038 and a polymorph patent expiring in 2039.
• The drug targets severe, refractory anaphylaxis, a significant unmet medical need with an estimated addressable market of $2 billion.
• Key competitive threats include established epinephrine auto-injectors and emerging novel therapies.
• Manufacturing and supply chain are secured through contract manufacturing with dual sourcing for critical raw materials.
• Potential IP challenges exist from alternative synthetic routes and generic challenges under the Hatch-Waxman Act.
• Financial projections indicate peak sales of $750 million, with a potential market capitalization of $3 billion to $4.5 billion.

Frequently Asked Questions

1. What is the primary mechanism of action for XTRELUS? XTRELUS is a small molecule inhibitor designed to block a specific signaling pathway that drives the severe inflammatory cascade associated with anaphylaxis.

2. What is the projected timeline for XTRELUS market launch? Following the anticipated NDA submission in Q1 2025, regulatory approval and subsequent market launch are projected for late 2025 or early 2026, contingent on FDA review timelines.

3. Are there any known significant side effects from XTRELUS in clinical trials? Phase II trials indicated common side effects including headache and mild gastrointestinal upset. A full safety profile will be detailed in the upcoming Phase III trial results and subsequent NDA submission.

4. What is the intellectual property strategy to defend against potential generic challenges? The company is pursuing a comprehensive IP strategy including filing continuation and divisional applications for existing patents, seeking additional patents for new formulations and methods of use, and actively monitoring the patent landscape for potential infringements or invalidity challenges.

5. What is the estimated annual cost of XTRELUS per patient? The projected average wholesale price (AWP) is $500 per dose, with an estimated annual requirement of two doses per patient, leading to an estimated annual cost of $1,000 per patient, excluding potential discounts or rebates.

Citations

[1] U.S. Patent No. 10,584,123. (2020). Composition of Matter for Vubloket. United States Patent and Trademark Office. [2] U.S. Patent No. 11,208,543. (2021). Crystalline Forms of Vubloket. United States Patent and Trademark Office. [3] Investigational New Drug (IND) Application for Vubloket. (2017). U.S. Food and Drug Administration. [4] World Intellectual Property Organization (WIPO). (2022). Patent Application WO2022/193856 A1. [5] Industry Market Analysis Report. (2023). Anaphylaxis Treatment Market Size and Trends. Pharmaceutical Market Research Group.